Skip to main content

Table 3 HPV prevalence and genotype distribution among HIV-1 seropositive and HIV-seronegative women in Cape Coast, Ghana

From: Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women

HPV genotypes HIV-1 positive (N = 160) HIV negative (N = 169) P-value
n (%) n (%)
HPV 16 17 (10.6) 1 (0.6) <0.0001
HPV 18 17 (10.6) 3 (1.8) 0.001
HPV 31 13 (8.1) 1 (0.6) 0.001
HPV 33 8 (5.0) 7 (4.1) 0.71
HPV 35 19 (11.9) 9 (5.3) 0.03
HPV 39 7 (4.4) 3 (1.8) 0.17
HPV 45 10 (6.3) 2 (1.2) 0.01
HPV 51 2 (1.3) 0 (0.0) 0.14
HPV 52 19 (11.9) 4 (2.4) 0.001
HPV 56 13 (8.1) 6 (3.6) 0.07
HPV 58 18 (11.3) 7 (4.1) 0.01
HPV 59 8 (5.0) 2 (1.2) 0.04
HPV 68 15 (9.4) 3 (1.8) 0.002
Any HPV 120 (75.0) 72 (42.6) <0.0001
Any hr.-HPV 105 (65.6) 51 (30.2) <0.0001
HPV 16/18 (bivalent vaccine types) 34 (21.3) 4 (2.4) <0.0001
HPV 16/18/6/11 (quadrivalent vaccine types) 53 (33.1) 7 (4.1) <0.0001
HPV 16/18/31/33/45/52/58/6/11 (nonavalent vaccine types) 89 (55.6) 29 (17.2) <0.0001
Low risk types only 15 (9.4) 21 (12.4) 0.38
HPV 6 12 (7.5) 1 (0.6) 0.001
HPV 11 10 (6.3) 2 (1.2) 0.01
HPV 6 and/or 11 21 (13.1) 3 (1.8) <0.0001
Multiple types
 2–5 64 (52.5) 36 (21.3) <0.0001
  > 5 13 (8.1) 0 (0.0) <0.0001